169 related articles for article (PubMed ID: 34250393)
21. Prognostic impact of postoperative 123I-metaiodobenzylguanidine scintigraphy: added value of SPECT/CT and semiquantification of the uptake at the surgical site.
Gauthé M; Breton M; Jehanno N; Cellier C; Michon J; Sarnacki S; Schleiermacher G; Wartski M
Q J Nucl Med Mol Imaging; 2020 Mar; 64(1):131-138. PubMed ID: 29409315
[TBL] [Abstract][Full Text] [Related]
22. New semi-quantitative 123I-MIBG estimation method compared with scoring system in follow-up of advanced neuroblastoma: utility of total MIBG retention ratio versus scoring method.
Sano Y; Okuyama C; Iehara T; Matsushima S; Yamada K; Hosoi H; Nishimura T
Ann Nucl Med; 2012 Jul; 26(6):462-70. PubMed ID: 22528971
[TBL] [Abstract][Full Text] [Related]
23. Solitary Dural Metastasis From Neuroblastoma Detected by 123 I-MIBG SPECT/CT.
Lu X; Xu Y; Wang W; Yang J
Clin Nucl Med; 2024 Feb; 49(2):198-200. PubMed ID: 38015714
[TBL] [Abstract][Full Text] [Related]
24. Renal Metastasis From Neuroblastoma Shown on MIBG Imaging.
Wen Z; Zhuang H
Clin Nucl Med; 2020 Jan; 45(1):87-89. PubMed ID: 31714275
[TBL] [Abstract][Full Text] [Related]
25. Likelihood of bone recurrence in prior sites of metastasis in patients with high-risk neuroblastoma.
Polishchuk AL; Li R; Hill-Kayser C; Little A; Hawkins RA; Hamilton J; Lau M; Tran HC; Strahlendorf C; Lemons RS; Weinberg V; Matthay KK; DuBois SG; Marcus KJ; Bagatell R; Haas-Kogan DA
Int J Radiat Oncol Biol Phys; 2014 Jul; 89(4):839-45. PubMed ID: 24867534
[TBL] [Abstract][Full Text] [Related]
26. Radioiodinated meta-iodobenzylguanidine in the diagnosis of childhood neuroblastoma.
Claudiani F; Stimamiglio P; Bertolazzi L; Cabria M; Conte M; Villavecchia GP; Garaventa A; Lanino E; De Bernardi B; Scopinaro G
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):21-4. PubMed ID: 9002744
[TBL] [Abstract][Full Text] [Related]
27. Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr 3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine.
Kroiss A; Putzer D; Uprimny C; Decristoforo C; Gabriel M; Santner W; Kranewitter C; Warwitz B; Waitz D; Kendler D; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2011 May; 38(5):865-73. PubMed ID: 21279352
[TBL] [Abstract][Full Text] [Related]
28. Increased Gastric MIBG Activity as a Normal Variant.
Bai X; Wang X; Zhuang H
Clin Nucl Med; 2019 Sep; 44(9):761-763. PubMed ID: 31058691
[TBL] [Abstract][Full Text] [Related]
29. Comparison of diagnostic value of I-123 MIBG and high-dose I-131 MIBG scintigraphy including incremental value of SPECT/CT over planar image in patients with malignant pheochromocytoma/paraganglioma and neuroblastoma.
Fukuoka M; Taki J; Mochizuki T; Kinuya S
Clin Nucl Med; 2011 Jan; 36(1):1-7. PubMed ID: 21157198
[TBL] [Abstract][Full Text] [Related]
30. Diagnosis, Treatment Response, and Prognosis: The Role of
Piccardo A; Morana G; Puntoni M; Campora S; Sorrentino S; Zucchetta P; Ugolini M; Conte M; Cistaro A; Ferrarazzo G; Pescetto M; Lattuada M; Bottoni G; Garaventa A; Giovanella L; Lopci E
J Nucl Med; 2020 Mar; 61(3):367-374. PubMed ID: 31541036
[TBL] [Abstract][Full Text] [Related]
31. Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis.
Marachelian A; Villablanca JG; Liu CW; Liu B; Goodarzian F; Lai HA; Shimada H; Tran HC; Parra JA; Gallego R; Bedrossian N; Young S; Czarnecki S; Kennedy R; Weiss BD; Goldsmith K; Granger M; Matthay KK; Groshen S; Asgharzadeh S; Sposto R; Seeger RC
Clin Cancer Res; 2017 Sep; 23(18):5374-5383. PubMed ID: 28559462
[No Abstract] [Full Text] [Related]
32. Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology Group.
Villablanca JG; London WB; Naranjo A; McGrady P; Ames MM; Reid JM; McGovern RM; Buhrow SA; Jackson H; Stranzinger E; Kitchen BJ; Sondel PM; Parisi MT; Shulkin B; Yanik GA; Cohn SL; Reynolds CP
Clin Cancer Res; 2011 Nov; 17(21):6858-66. PubMed ID: 21908574
[TBL] [Abstract][Full Text] [Related]
33. Alteration of myocardial metaiodobenzylguanidine uptake after treatment of phaeochromocytoma and neuroblastoma.
Suga K; Ogasawara N; Ariga M; Motoyama K; Hara A; Kume N; Matsunaga N
Eur J Nucl Med; 2000 May; 27(5):574-82. PubMed ID: 10853814
[TBL] [Abstract][Full Text] [Related]
34. I-123-MIBG scintigraphy in patients with neuroblastoma.
Rogasch JMM; Amthauer H; Furth C; Hundsdoerfer P; Wedel F; Schatka I
Nuklearmedizin; 2018 Feb; 57(1):35-39. PubMed ID: 29536499
[TBL] [Abstract][Full Text] [Related]
35. Follow-up in neuroblastoma: comparison of metaiodobenzylguanidine and a chimeric anti-GD2 antibody for detection of tumor relapse and therapy response.
Reuland P; Geiger L; Thelen MH; Handgretinger R; Haase B; Müller-Schauenburg W; Niethammer D; Bares R
J Pediatr Hematol Oncol; 2001 Oct; 23(7):437-42. PubMed ID: 11878578
[TBL] [Abstract][Full Text] [Related]
36. MIBG Uptake in Pancreas as a Normal Variant.
Wang Y; Yang X; Wang W; Yang J
Clin Nucl Med; 2022 Feb; 47(2):168-171. PubMed ID: 34183500
[TBL] [Abstract][Full Text] [Related]
37. Neuroblastoma Presenting as Non-MIBG-Avid Widespread Soft Tissue Metastases Without Bone Involvement Revealed by FDG PET/CT Imaging.
Tolboom N; Servaes SE; Zhuang H
Clin Nucl Med; 2017 Aug; 42(8):643-644. PubMed ID: 28525450
[TBL] [Abstract][Full Text] [Related]
38. Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients.
Kushner BH; Yeung HW; Larson SM; Kramer K; Cheung NK
J Clin Oncol; 2001 Jul; 19(14):3397-405. PubMed ID: 11454888
[TBL] [Abstract][Full Text] [Related]
39. Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome.
Padovan-Merhar OM; Raman P; Ostrovnaya I; Kalletla K; Rubnitz KR; Sanford EM; Ali SM; Miller VA; Mossé YP; Granger MP; Weiss B; Maris JM; Modak S
PLoS Genet; 2016 Dec; 12(12):e1006501. PubMed ID: 27997549
[TBL] [Abstract][Full Text] [Related]
40. Predictors of response, progression-free survival, and overall survival using NANT Response Criteria (v1.0) in relapsed and refractory high-risk neuroblastoma.
Villablanca JG; Ji L; Shapira-Lewinson A; Marachelian A; Shimada H; Hawkins RA; Pampaloni M; Lai H; Goodarzian F; Sposto R; Park JR; Matthay KK
Pediatr Blood Cancer; 2018 May; 65(5):e26940. PubMed ID: 29350464
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
